However, on the cash pay, we're offering it at about a more than 65% discount from $255 to $85 a capsule, making it affordable for folks who travel for business or pleasure, engage in these motion sickness activities.

May 6, 2026 / receipt, needs a key / Male Speaker, other | earnings call 2026-05-06 | transcript 5f2f3986-99d3-421d-ac98-8d24c4e45950 | chars 38934-39151 | segment 39

An eventual approval for this indication if received will significantly expand the addressable patient population with approximately 30% of the U.S. population reported to suffer from motion sickness under ordinary travel conditions that include sea, air, and land.

May 8, 2024 / receipt, needs a key / Dr. Mahalis Polymeropoulos, CEO | earnings call 2024-05-08 | transcript 07145980-0a1b-4190-94a8-cea816def0d6 | chars 11135-11400 | segment 10

On tradipitin and beyond the gastroparesis program, the Odyssey study for tradipitin based with COVID-19 pneumonia is growing, while the tradipitin motion sickness study is on hold due to pandemic-related travel restrictions.

Jul 28, 2021 / receipt, needs a key / Mahalas Polymeropoulos, CEO | earnings call 2021-07-28 | transcript 28f8b417-2d28-4272-9d7f-8b92aec7fd07 | chars 12045-12270 | segment 11

Vanda’s ability to increase market awareness of Non-24 and SMS and market acceptance of HETLIOZ®;

ir_statement / Sep 11, 2026 / receipt

Vanda’s ability to overcome the increased reimbursement challenges it faces as a result of declining third-party payor coverage;

ir_statement / Sep 11, 2026 / receipt

Vanda’s level of success in commercializing Fanapt® and HETLIOZ® in new markets;

ir_statement / Sep 11, 2026 / receipt

Fanapt® net product sales $150M - $170M

ir_statement / Sep 11, 2026 / receipt

Other net product sales $80M - $90M

ir_statement / Sep 11, 2026 / receipt

Total Revenues $230M - $260M

ir_statement / Sep 11, 2026 / receipt

Imminent Clinical and Regulatory Catalysts, with potential for significant commercial expansion in 2026 and 2027

ir_statement / Sep 11, 2026 / receipt

Robust Commercial Portfolio anchored by five FDA-approved brands:

ir_statement / Sep 11, 2026 / receipt

Robust Debt-Free Balance Sheet, providing support for commercial launches of NEREUS and BYSANTI

ir_statement / Sep 11, 2026 / receipt